首页 > 最新文献

Current Opinion in Pharmacology最新文献

英文 中文
The underlying mechanisms of acupuncture for alleviating pain-induced negative emotions: Synergistic regulation of multiple brain regions 针刺减轻疼痛负性情绪的潜在机制:多脑区的协同调节
IF 4.2 3区 医学 Q1 PHARMACOLOGY & PHARMACY Pub Date : 2025-12-08 DOI: 10.1016/j.coph.2025.102599
Zhen Liu , Chaoyang Zhang , Zelin Chen , Zhifang Xu , Tianyi Zhao
Brain regions associated with pain perception also subsume those involved in emotional regulation, which likely constitutes the physiological basis underlying the comorbidity of pain and negative emotions. Acupuncture has unique advantages compared with drugs. Studies have shown that acupuncture can achieve multi-targeted and bidirectional regulation, simultaneously improving pain and accompanying negative emotional symptoms without causing drug resistance or systemic toxicity. In the hippocampus, acupuncture may contribute to the regulation of painful emotional memory processing by inhibiting ventral hippocampal neuron apoptosis, promoting neurogenesis, and regulating synaptic plasticity. In the anterior cingulate cortex, acupuncture may partially reduce the perception and transmission of pain-related emotions by inhibiting the release of glutamate and the expression of its receptors, enhancing the inhibitory effect of GABAergic receptors. In the medial prefrontal cortex, acupuncture might alleviate inflammatory responses by inhibiting microglial activation and the release of pro-inflammatory cytokines, thereby preserving the integrity of the descending regulatory circuit for painful emotions. This protects the integrity of the descending pain-emotion regulatory circuit. In the amygdala, acupuncture may improve reward deficiency and fear-related abnormal synaptic plasticity by regulating the expression of dopamine receptors, thus avoiding the excessive amplification of pain emotions. This article reviews the mechanisms by which acupuncture improves the induced negative emotions, which is helpful to promote the integration of acupuncture as a complementary approach into the precision medical treatment system for chronic pain-induced anxiety, depression, or comorbidities, and provides a scientific basis for the application of non-pharmacological therapies in neuropsychiatric disorders.
与疼痛感知相关的大脑区域也包括那些参与情绪调节的区域,这可能构成了疼痛和负面情绪并存的生理基础。与药物相比,针灸具有独特的优势。研究表明,针灸可以实现多靶点、双向调节,同时改善疼痛和伴随的负面情绪症状,而不会产生耐药性和全身毒性。在海马体中,针刺可能通过抑制海马腹侧神经元凋亡、促进神经发生、调节突触可塑性来调节痛苦情绪记忆加工。在前扣带皮层,针刺可能通过抑制谷氨酸的释放及其受体的表达,增强gaba能受体的抑制作用,部分减少疼痛相关情绪的感知和传递。在内侧前额叶皮层,针灸可能通过抑制小胶质细胞的激活和促炎细胞因子的释放来减轻炎症反应,从而保持疼痛情绪下行调节回路的完整性。这保护了下行疼痛-情绪调节回路的完整性。在杏仁核中,针刺可能通过调节多巴胺受体的表达来改善奖励缺失和恐惧相关的突触异常可塑性,从而避免疼痛情绪的过度放大。本文综述了针刺改善负性情绪的机制,有助于促进针刺作为一种辅助手段融入慢性疼痛性焦虑、抑郁或合并症的精准医疗体系,并为非药物治疗在神经精神疾病中的应用提供科学依据。
{"title":"The underlying mechanisms of acupuncture for alleviating pain-induced negative emotions: Synergistic regulation of multiple brain regions","authors":"Zhen Liu ,&nbsp;Chaoyang Zhang ,&nbsp;Zelin Chen ,&nbsp;Zhifang Xu ,&nbsp;Tianyi Zhao","doi":"10.1016/j.coph.2025.102599","DOIUrl":"10.1016/j.coph.2025.102599","url":null,"abstract":"<div><div>Brain regions associated with pain perception also subsume those involved in emotional regulation, which likely constitutes the physiological basis underlying the comorbidity of pain and negative emotions. Acupuncture has unique advantages compared with drugs. Studies have shown that acupuncture can achieve multi-targeted and bidirectional regulation, simultaneously improving pain and accompanying negative emotional symptoms without causing drug resistance or systemic toxicity. In the hippocampus, acupuncture may contribute to the regulation of painful emotional memory processing by inhibiting ventral hippocampal neuron apoptosis, promoting neurogenesis, and regulating synaptic plasticity. In the anterior cingulate cortex, acupuncture may partially reduce the perception and transmission of pain-related emotions by inhibiting the release of glutamate and the expression of its receptors, enhancing the inhibitory effect of GABAergic receptors. In the medial prefrontal cortex, acupuncture might alleviate inflammatory responses by inhibiting microglial activation and the release of pro-inflammatory cytokines, thereby preserving the integrity of the descending regulatory circuit for painful emotions. This protects the integrity of the descending pain-emotion regulatory circuit. In the amygdala, acupuncture may improve reward deficiency and fear-related abnormal synaptic plasticity by regulating the expression of dopamine receptors, thus avoiding the excessive amplification of pain emotions. This article reviews the mechanisms by which acupuncture improves the induced negative emotions, which is helpful to promote the integration of acupuncture as a complementary approach into the precision medical treatment system for chronic pain-induced anxiety, depression, or comorbidities, and provides a scientific basis for the application of non-pharmacological therapies in neuropsychiatric disorders.</div></div>","PeriodicalId":50603,"journal":{"name":"Current Opinion in Pharmacology","volume":"86 ","pages":"Article 102599"},"PeriodicalIF":4.2,"publicationDate":"2025-12-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145840543","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
AI-powered intestinal ultrasound in inflammatory bowel disease: Advancing toward automated disease assessment 炎症性肠病的人工智能肠道超声:朝着疾病自动化评估的方向发展。
IF 4.2 3区 医学 Q1 PHARMACOLOGY & PHARMACY Pub Date : 2025-12-08 DOI: 10.1016/j.coph.2025.102598
Irene Zammarchi , Olga Maria Nardone , Rosanna Cannatelli , Subrata Ghosh , Chiara Ricci , Marietta Iacucci
The management of inflammatory bowel disease (IBD) relies on accurate disease assessment and close monitoring to guide therapy and evaluate treatment response. While endoscopy remains the gold standard for detecting mucosal inflammation, its invasiveness and inability to fully assess transmural disease or extraintestinal complications limit its use as a stand-alone tool. Cross-sectional imaging modalities, such as CT and MRI, provide accurate evaluations but are hindered by high cost, limited accessibility, and patient burden. Therefore, intestinal ultrasound (IUS) has emerged as a safe, non-invasive, and reproducible modality to evaluate transmural inflammation and complications in real time, making it increasingly relevant for both Crohn's disease and ulcerative colitis. However, challenges such as operator dependence, variability in image acquisition, and lack of standardize protocols have limited its widespread adoption.
Artificial intelligence (AI) offers transformative potential to overcome these barriers by automating image analysis, standardising interpretation, and reducing interobserver variability. Early applications have shown promise in bowel wall segmentation and thickness assessment, with future opportunities to further integrate imaging features with biomarkers, clinical data, and multi-omics for precision medicine.
This review aims to explore the current and future roles of IUS, summarizing the potential of AI in IUS to improve diagnostic accuracy, enhance disease monitoring, and enable personalized patient management. We will discuss the strengths and limitations of existing approaches, highlight barriers to clinical implementation, and outline perspectives on how AI-enhanced IUS may transform both research and routine care in IBD.
炎症性肠病(IBD)的管理依赖于准确的疾病评估和密切监测来指导治疗和评估治疗反应。虽然内窥镜检查仍然是检测粘膜炎症的金标准,但其侵入性和无法完全评估跨壁疾病或肠外并发症限制了其作为独立工具的使用。横断成像方式,如CT和MRI,提供准确的评估,但受到高成本、有限的可及性和患者负担的阻碍。因此,肠道超声(IUS)已成为一种安全、无创、可重复的实时评估跨壁炎症和并发症的方法,使其在克罗恩病和溃疡性结肠炎中越来越重要。然而,诸如操作员依赖性、图像采集的可变性以及缺乏标准化协议等挑战限制了其广泛采用。人工智能(AI)通过自动化图像分析、标准化解释和减少观察者之间的差异,提供了克服这些障碍的变革性潜力。早期应用于肠壁分割和厚度评估,未来有机会进一步将成像特征与生物标志物、临床数据和精确医学的多组学相结合。本文旨在探讨IUS目前和未来的作用,总结AI在IUS中提高诊断准确性、加强疾病监测和实现个性化患者管理的潜力。我们将讨论现有方法的优势和局限性,强调临床实施的障碍,并概述人工智能增强的IUS如何改变IBD的研究和常规护理的观点。
{"title":"AI-powered intestinal ultrasound in inflammatory bowel disease: Advancing toward automated disease assessment","authors":"Irene Zammarchi ,&nbsp;Olga Maria Nardone ,&nbsp;Rosanna Cannatelli ,&nbsp;Subrata Ghosh ,&nbsp;Chiara Ricci ,&nbsp;Marietta Iacucci","doi":"10.1016/j.coph.2025.102598","DOIUrl":"10.1016/j.coph.2025.102598","url":null,"abstract":"<div><div>The management of inflammatory bowel disease (IBD) relies on accurate disease assessment and close monitoring to guide therapy and evaluate treatment response. While endoscopy remains the gold standard for detecting mucosal inflammation, its invasiveness and inability to fully assess transmural disease or extraintestinal complications limit its use as a stand-alone tool. Cross-sectional imaging modalities, such as CT and MRI, provide accurate evaluations but are hindered by high cost, limited accessibility, and patient burden. Therefore, intestinal ultrasound (IUS) has emerged as a safe, non-invasive, and reproducible modality to evaluate transmural inflammation and complications in real time, making it increasingly relevant for both Crohn's disease and ulcerative colitis. However, challenges such as operator dependence, variability in image acquisition, and lack of standardize protocols have limited its widespread adoption.</div><div>Artificial intelligence (AI) offers transformative potential to overcome these barriers by automating image analysis, standardising interpretation, and reducing interobserver variability. Early applications have shown promise in bowel wall segmentation and thickness assessment, with future opportunities to further integrate imaging features with biomarkers, clinical data, and multi-omics for precision medicine.</div><div>This review aims to explore the current and future roles of IUS, summarizing the potential of AI in IUS to improve diagnostic accuracy, enhance disease monitoring, and enable personalized patient management. We will discuss the strengths and limitations of existing approaches, highlight barriers to clinical implementation, and outline perspectives on how AI-enhanced IUS may transform both research and routine care in IBD.</div></div>","PeriodicalId":50603,"journal":{"name":"Current Opinion in Pharmacology","volume":"86 ","pages":"Article 102598"},"PeriodicalIF":4.2,"publicationDate":"2025-12-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145866395","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The role of plant-derived compounds in anti-obesity drug discovery: A molecular perspective 植物源性化合物在抗肥胖药物发现中的作用:分子视角。
IF 4.2 3区 医学 Q1 PHARMACOLOGY & PHARMACY Pub Date : 2025-11-28 DOI: 10.1016/j.coph.2025.102597
Vetriselvan Subramaniyan , Ram Narayanan Ravi , Sammra Maqsood , Sachin Kumar Singh , Vellapandian Chitra , Kamal Dua , Brian G. Oliver , Sivaraman Dhanasekaran , Gaurav Gupta , Thakur Gurjeet Singh
Obesity is a complex and multifaceted disease associated with metabolic diseases and severe health problems worldwide. There is an urgent need for novel therapeutic strategies since the currently available treatment options are often ineffective or cause adverse effects. Since they can modulate crucial biochemical pathways,phytochemicals, which are plant-derived compounds, provide a promising approach to the design of anti-obesity drugs. Such ways through which these substances work are preventing adipogenesis, regulating lipid metabolism, dropping inflammation, improving insulin sensitivity, and reestablishing energy balance. These are some of the main topics of this review. Numerous phytochemicals have emerged as auspicious agents targeting adipocytes, gut bacteria, and essential enzymes elaborate in metabolic pathways associated to obesity, such as polyphenols, flavonoids, and terpenes. Additional preclinical and clinical data testify to the rationality of these molecules toward their intended therapy aims. Prospects for incorporating phytochemicals into treatment plans for obesity are deliberated next, along with potential synergistic effects of plant bioactives and allegations for polyherbal formulations.
肥胖是一种复杂的、多方面的疾病,与世界范围内的代谢性疾病和严重的健康问题有关。由于目前可用的治疗方案往往无效或引起不良反应,因此迫切需要新的治疗策略。由于植物化学物质可以调节关键的生化途径,植物化学物质作为植物衍生的化合物,为设计抗肥胖药物提供了一种有希望的方法。这些物质的作用方式包括:防止脂肪生成、调节脂质代谢、降低炎症、改善胰岛素敏感性和重建能量平衡。这些是本综述的一些主要主题。许多植物化学物质已经成为针对脂肪细胞、肠道细菌和与肥胖相关的代谢途径中的必需酶的吉祥剂,如多酚、类黄酮和萜烯。额外的临床前和临床数据证明了这些分子对其预期治疗目标的合理性。接下来将讨论将植物化学物质纳入肥胖治疗计划的前景,以及植物生物活性物质的潜在协同效应和对多草药配方的指控。
{"title":"The role of plant-derived compounds in anti-obesity drug discovery: A molecular perspective","authors":"Vetriselvan Subramaniyan ,&nbsp;Ram Narayanan Ravi ,&nbsp;Sammra Maqsood ,&nbsp;Sachin Kumar Singh ,&nbsp;Vellapandian Chitra ,&nbsp;Kamal Dua ,&nbsp;Brian G. Oliver ,&nbsp;Sivaraman Dhanasekaran ,&nbsp;Gaurav Gupta ,&nbsp;Thakur Gurjeet Singh","doi":"10.1016/j.coph.2025.102597","DOIUrl":"10.1016/j.coph.2025.102597","url":null,"abstract":"<div><div>Obesity is a complex and multifaceted disease associated with metabolic diseases and severe health problems worldwide. There is an urgent need for novel therapeutic strategies since the currently available treatment options are often ineffective or cause adverse effects. Since they can modulate crucial biochemical pathways,phytochemicals, which are plant-derived compounds, provide a promising approach to the design of anti-obesity drugs. Such ways through which these substances work are preventing adipogenesis, regulating lipid metabolism, dropping inflammation, improving insulin sensitivity, and reestablishing energy balance. These are some of the main topics of this review. Numerous phytochemicals have emerged as auspicious agents targeting adipocytes, gut bacteria, and essential enzymes elaborate in metabolic pathways associated to obesity, such as polyphenols, flavonoids, and terpenes. Additional preclinical and clinical data testify to the rationality of these molecules toward their intended therapy aims. Prospects for incorporating phytochemicals into treatment plans for obesity are deliberated next, along with potential synergistic effects of plant bioactives and allegations for polyherbal formulations.</div></div>","PeriodicalId":50603,"journal":{"name":"Current Opinion in Pharmacology","volume":"86 ","pages":"Article 102597"},"PeriodicalIF":4.2,"publicationDate":"2025-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145795744","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Innovative pipeline therapeutics in inflammatory bowel disease: Anti-tumor necrosis factor-like ligand 1A and bispecific antibodies 炎症性肠病的创新管道治疗:抗肿瘤坏死因子样配体1A和双特异性抗体
IF 4.2 3区 医学 Q1 PHARMACOLOGY & PHARMACY Pub Date : 2025-11-25 DOI: 10.1016/j.coph.2025.102596
Maria Manuela Estevinho , Nurulamin M. Noor
There has been significant progress made in inflammatory bowel disease (IBD) over the last couple of decades, with a rapidly increasing number of biologic and small molecules treatments. Coupled with a better understanding of when and how to use treatments appropriately, this has resulted in substantial and meaningful improvement in outcomes for many patients. However, an ongoing issue is that around 30–40% of patients either do not respond or lose response to currently available treatments over time, underscoring the need for further novel therapeutic targets and approaches.
Two particularly exciting novel approaches include a novel class of medications targeting tumor necrosis factor-like ligand 1A (TL1A) and the engagement in two pathogenic pathways simultaneously through the use of bispecific antibodies. The development of both of these potential treatment approaches has been built on decades of translational studies, including initial genetic discovery and immune functional validation. The class of molecules targeting TL1A has shown high potency in the pre-clinical setting and emerging data from early-phase interventional clinical trials have been encouraging. Bispecific antibodies have been used so far mostly in the fields of hematology and oncology, but with promising initial findings in IBD that targeting multiple pathways at once, may offer the prospect of greater remission rates or more durable remission than current strategies seeking to target single immunological pathways in isolation. This narrative review presents the latest evidence evaluating TL1A inhibition and bispecific antibodies, including the development pipeline for these molecules as innovative approaches for the next generation of IBD treatments.
在过去的几十年里,随着生物和小分子治疗方法的迅速增加,炎症性肠病(IBD)的治疗取得了重大进展。再加上更好地了解何时以及如何适当地使用治疗方法,这为许多患者的预后带来了实质性和有意义的改善。然而,一个持续存在的问题是,随着时间的推移,大约30-40%的患者对目前可用的治疗没有反应或失去反应,这强调了进一步开发新的治疗靶点和方法的必要性。两种特别令人兴奋的新方法包括一类针对肿瘤坏死因子样配体1A (TL1A)的新型药物,以及通过使用双特异性抗体同时参与两种致病途径。这两种潜在治疗方法的发展都建立在数十年的转化研究基础上,包括最初的基因发现和免疫功能验证。靶向TL1A的分子类别在临床前环境中显示出高效力,早期介入性临床试验的新数据令人鼓舞。到目前为止,双特异性抗体主要用于血液学和肿瘤学领域,但在IBD中有希望的初步发现,同时靶向多种途径,可能比目前寻求孤立靶向单一免疫途径的策略提供更高的缓解率或更持久的缓解。这篇叙述性综述介绍了评估TL1A抑制和双特异性抗体的最新证据,包括这些分子作为下一代IBD治疗创新方法的开发管道。
{"title":"Innovative pipeline therapeutics in inflammatory bowel disease: Anti-tumor necrosis factor-like ligand 1A and bispecific antibodies","authors":"Maria Manuela Estevinho ,&nbsp;Nurulamin M. Noor","doi":"10.1016/j.coph.2025.102596","DOIUrl":"10.1016/j.coph.2025.102596","url":null,"abstract":"<div><div>There has been significant progress made in inflammatory bowel disease (IBD) over the last couple of decades, with a rapidly increasing number of biologic and small molecules treatments. Coupled with a better understanding of when and how to use treatments appropriately, this has resulted in substantial and meaningful improvement in outcomes for many patients. However, an ongoing issue is that around 30–40% of patients either do not respond or lose response to currently available treatments over time, underscoring the need for further novel therapeutic targets and approaches.</div><div>Two particularly exciting novel approaches include a novel class of medications targeting tumor necrosis factor-like ligand 1A (TL1A) and the engagement in two pathogenic pathways simultaneously through the use of bispecific antibodies. The development of both of these potential treatment approaches has been built on decades of translational studies, including initial genetic discovery and immune functional validation. The class of molecules targeting TL1A has shown high potency in the pre-clinical setting and emerging data from early-phase interventional clinical trials have been encouraging. Bispecific antibodies have been used so far mostly in the fields of hematology and oncology, but with promising initial findings in IBD that targeting multiple pathways at once, may offer the prospect of greater remission rates or more durable remission than current strategies seeking to target single immunological pathways in isolation. This narrative review presents the latest evidence evaluating TL1A inhibition and bispecific antibodies, including the development pipeline for these molecules as innovative approaches for the next generation of IBD treatments.</div></div>","PeriodicalId":50603,"journal":{"name":"Current Opinion in Pharmacology","volume":"86 ","pages":"Article 102596"},"PeriodicalIF":4.2,"publicationDate":"2025-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145738713","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Nutritional composition of diets for inducing and maintaining remission in inflammatory bowel diseases: from bedside to plate 诱导和维持炎症性肠病缓解的饮食营养成分:从床边到餐盘。
IF 4.2 3区 医学 Q1 PHARMACOLOGY & PHARMACY Pub Date : 2025-11-20 DOI: 10.1016/j.coph.2025.102587
L. Godny , T. Pfeffer-Gik , S. Elial-Fatal , S. Shakhman , I. Dotan
There is growing interest in the role of dietary therapies in the management of inflammatory bowel diseases (IBDs), including Crohn’s disease (CD) and ulcerative colitis (UC). This narrative review synthesizes current evidence on the nutritional composition and clinical implications of diets evaluated for IBD across different disease stages and phenotypes. In active CD, dietary strategies commonly focus on the exclusion of specific components believed to promote inflammation, such as food additives and ultra processed foods. This is in contrast to exclusive enteral nutrition or Crohn’s disease exclusion diet (CDED) + partial enteral nutrition (PEN), which, despite containing food additives such as emulsifiers, remains the main established and efficacious dietary therapies for active CD. Some diets also restrict gluten and lactose during their initial phases. In active UC, dietary approaches emphasize the modulation of microbial metabolism, particularly by reducing colonic sulfide production and enhancing the production of short-chain fatty acids through reduced intake of animal-based foods and increased consumption of fermentable fibers and resistant starch. For maintenance of remission in both CD and UC, data supporting specific dietary approaches are currently limited. However, the emphasis shifts toward sustainability, favoring flexible, plant-based, minimally processed dietary patterns, such as the Mediterranean diet (MED). Future well-designed, adequately powered clinical trials are required to confirm efficacy, clarify long-term outcomes, and establish disease-specific dietary recommendations. Personalized dietary counseling by trained IBD dietitians, as part of the multidisciplinary team, remains central to integrating these approaches into care, optimizing adherence, and ensuring nutritional adequacy and optimal quality of life.
人们对饮食疗法在炎症性肠病(IBDs)治疗中的作用越来越感兴趣,包括克罗恩病(CD)和溃疡性结肠炎(UC)。这篇叙述性综述综合了目前在不同疾病阶段和表型中评估IBD饮食的营养成分和临床意义的证据。在活动性乳糜泻中,饮食策略通常侧重于排除被认为会促进炎症的特定成分,如食品添加剂和超加工食品。这与纯肠内营养或克罗恩病排除饮食(CDED) +部分肠内营养(PEN)形成对比,后者尽管含有乳化剂等食品添加剂,但仍然是治疗活性乳糜泻的主要既定和有效的饮食疗法。一些饮食在初始阶段也限制麸质和乳糖。在活性UC中,饮食方法强调微生物代谢的调节,特别是通过减少动物性食物的摄入和增加可发酵纤维和抗性淀粉的消耗来减少结肠硫化物的产生和促进短链脂肪酸的产生。对于维持CD和UC的缓解,目前支持特定饮食方法的数据有限。然而,重点转向可持续性,倾向于灵活的、以植物为基础的、最少加工的饮食模式,如地中海饮食(MED)。未来需要精心设计、充分支持的临床试验来确认疗效、阐明长期结果,并建立针对疾病的饮食建议。作为多学科团队的一部分,由训练有素的IBD营养师提供个性化饮食咨询,对于将这些方法整合到护理中,优化依从性,确保营养充足和最佳生活质量仍然至关重要。
{"title":"Nutritional composition of diets for inducing and maintaining remission in inflammatory bowel diseases: from bedside to plate","authors":"L. Godny ,&nbsp;T. Pfeffer-Gik ,&nbsp;S. Elial-Fatal ,&nbsp;S. Shakhman ,&nbsp;I. Dotan","doi":"10.1016/j.coph.2025.102587","DOIUrl":"10.1016/j.coph.2025.102587","url":null,"abstract":"<div><div>There is growing interest in the role of dietary therapies in the management of inflammatory bowel diseases (IBDs), including Crohn’s disease (CD) and ulcerative colitis (UC). This narrative review synthesizes current evidence on the nutritional composition and clinical implications of diets evaluated for IBD across different disease stages and phenotypes. In active CD, dietary strategies commonly focus on the exclusion of specific components believed to promote inflammation, such as food additives and ultra processed foods. This is in contrast to exclusive enteral nutrition or Crohn’s disease exclusion diet (CDED) + partial enteral nutrition (PEN), which, despite containing food additives such as emulsifiers, remains the main established and efficacious dietary therapies for active CD. Some diets also restrict gluten and lactose during their initial phases. In active UC, dietary approaches emphasize the modulation of microbial metabolism, particularly by reducing colonic sulfide production and enhancing the production of short-chain fatty acids through reduced intake of animal-based foods and increased consumption of fermentable fibers and resistant starch. For maintenance of remission in both CD and UC, data supporting specific dietary approaches are currently limited. However, the emphasis shifts toward sustainability, favoring flexible, plant-based, minimally processed dietary patterns, such as the Mediterranean diet (MED). Future well-designed, adequately powered clinical trials are required to confirm efficacy, clarify long-term outcomes, and establish disease-specific dietary recommendations. Personalized dietary counseling by trained IBD dietitians, as part of the multidisciplinary team, remains central to integrating these approaches into care, optimizing adherence, and ensuring nutritional adequacy and optimal quality of life.</div></div>","PeriodicalId":50603,"journal":{"name":"Current Opinion in Pharmacology","volume":"86 ","pages":"Article 102587"},"PeriodicalIF":4.2,"publicationDate":"2025-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145727044","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Beyond tumor necrosis factor and interleukin-12/23: The rise of interleukin-23 inhibitors in inflammatory bowel disease management 肿瘤坏死因子和白细胞介素-12/23:白细胞介素-23抑制剂在炎症性肠病治疗中的应用
IF 4.2 3区 医学 Q1 PHARMACOLOGY & PHARMACY Pub Date : 2025-11-20 DOI: 10.1016/j.coph.2025.102583
Catarina Costa , Nurulamin M. Noor , Maria Manuela Estevinho
Interleukin-23 (IL-23) has been identified as a key driver of chronic intestinal inflammation and treatment resistance, particularly in patients who have failed anti-tumor necrosis factor (TNF) therapy. Genetic studies and preclinical models have confirmed IL-23's pivotal role in promoting both innate and adaptive immune responses in the gut. This review examines the biology of IL-23 and the evidence supporting its targeting in inflammatory bowel disease (IBD). Clinical trials of IL-23p19 inhibitors–such as risankizumab, mirikizumab, and guselkumab–have shown promising results in patients with moderate-to-severe Crohn's disease and ulcerative colitis, with improvements in clinical and endoscopic outcomes and favorable safety profiles. Recent real-world data further support their effectiveness, including in treatment-experienced populations. With regulatory approvals expanding in both the United States and Europe, IL-23 inhibitors are now firmly established as a part of the IBD treatment landscape. Looking ahead, efforts are underway to identify biomarkers of response and to explore oral IL-23 inhibitors, with the goal of advancing more personalized and accessible care.
白细胞介素-23 (IL-23)已被确定为慢性肠道炎症和治疗耐药性的关键驱动因素,特别是在抗肿瘤坏死因子(TNF)治疗失败的患者中。遗传学研究和临床前模型证实了IL-23在促进肠道先天和适应性免疫反应中的关键作用。本文综述了IL-23的生物学特性以及支持其在炎症性肠病(IBD)中的靶向性的证据。IL-23p19抑制剂(如risankizumab、mirikizumab和guselkumumab)的临床试验显示,在中度至重度克罗恩病和溃疡性结肠炎患者中,IL-23p19抑制剂(如risankizumab、mirikizumab和guselkumumab)具有良好的临床和内镜结果改善以及良好的安全性。最近的实际数据进一步支持其有效性,包括在有治疗经验的人群中。随着美国和欧洲监管机构批准的扩大,IL-23抑制剂现在已牢固地确立为IBD治疗领域的一部分。展望未来,人们正在努力确定反应的生物标志物,并探索口服IL-23抑制剂,以推进更加个性化和可及的护理。
{"title":"Beyond tumor necrosis factor and interleukin-12/23: The rise of interleukin-23 inhibitors in inflammatory bowel disease management","authors":"Catarina Costa ,&nbsp;Nurulamin M. Noor ,&nbsp;Maria Manuela Estevinho","doi":"10.1016/j.coph.2025.102583","DOIUrl":"10.1016/j.coph.2025.102583","url":null,"abstract":"<div><div>Interleukin-23 (IL-23) has been identified as a key driver of chronic intestinal inflammation and treatment resistance, particularly in patients who have failed anti-<em>tumor necrosis factor (</em>TNF) therapy. Genetic studies and preclinical models have confirmed IL-23's pivotal role in promoting both innate and adaptive immune responses in the gut. This review examines the biology of IL-23 and the evidence supporting its targeting in inflammatory bowel disease (IBD). Clinical trials of IL-23p19 inhibitors–such as risankizumab, mirikizumab, and guselkumab–have shown promising results in patients with moderate-to-severe Crohn's disease and ulcerative colitis, with improvements in clinical and endoscopic outcomes and favorable safety profiles. Recent real-world data further support their effectiveness, including in treatment-experienced populations. With regulatory approvals expanding in both the United States and Europe, IL-23 inhibitors are now firmly established as a part of the IBD treatment landscape. Looking ahead, efforts are underway to identify biomarkers of response and to explore oral IL-23 inhibitors, with the goal of advancing more personalized and accessible care.</div></div>","PeriodicalId":50603,"journal":{"name":"Current Opinion in Pharmacology","volume":"86 ","pages":"Article 102583"},"PeriodicalIF":4.2,"publicationDate":"2025-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145749071","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
From one-size-fits-all to phenotype-based pharmacotherapy: How far are we in obesity management? 从一刀切到基于表型的药物治疗:我们在肥胖管理方面走了多远?
IF 4.2 3区 医学 Q1 PHARMACOLOGY & PHARMACY Pub Date : 2025-11-19 DOI: 10.1016/j.coph.2025.102589
Theocharis Koufakis , Luca Busetto
Obesity is a global health crisis, projected to affect over one billion adults by 2030. Lifestyle modification strategies—diet, physical activity, and behavioral therapy—have achieved only modest and often unsustainable outcomes. Pharmacotherapy has therefore emerged as a cornerstone of modern obesity care. Glucagon-like peptide-1 (GLP-1) receptor agonists and dual incretin agents such as tirzepatide have demonstrated unprecedented efficacy, with weight reductions approaching surgical outcomes in some populations while improving glycemic and cardiometabolic parameters. These therapeutic advances align with recognition of the pathophysiological heterogeneity of obesity, often conceptualized through four phenotypes: “hungry brain” (impaired satiation), “hungry gut” (impaired satiety), “emotional hunger” (reward-driven eating), and “slow burn” (impaired metabolism). This framework offers a rationale for targeted interventions—GLP-1 receptor agonists for satiety-related phenotypes, naltrexone–bupropion for reward-driven eating, and dual incretin therapies for metabolic inefficiency. Beyond pharmacology, accumulating evidence indicates that surgical outcomes may also differ across patient subgroups, suggesting that phenotype-guided strategies could refine not only medical therapy but also surgical decision-making. However, these phenotypes remain heuristic, with overlapping traits, limited validation, and uncertain predictive value. Future research should refine phenotypic classification, identify reliable biomarkers, and conduct phenotype-stratified clinical trials to confirm matching of pharmacological and surgical interventions.
肥胖是一个全球性的健康危机,预计到2030年将影响超过10亿成年人。生活方式的改变策略——饮食、体育活动和行为疗法——只取得了适度的效果,而且往往是不可持续的结果。因此,药物治疗已成为现代肥胖治疗的基石。胰高血糖素样肽-1 (GLP-1)受体激动剂和双重肠促胰岛素制剂(如替西肽)已显示出前所未有的疗效,在一些人群中,体重减轻接近手术效果,同时改善血糖和心脏代谢参数。这些治疗进展与对肥胖病理生理异质性的认识一致,通常通过四种表型来概念化:“饥饿的大脑”(饱腹感受损),“饥饿的肠道”(饱腹感受损),“情绪饥饿”(奖励驱动进食)和“缓慢燃烧”(代谢受损)。该框架为靶向干预提供了基本原理- glp -1受体激动剂治疗饱腹感相关表型,纳曲酮-安非他酮治疗奖励驱动进食,双肠促胰岛素治疗代谢效率低下。除了药理学,越来越多的证据表明,手术结果也可能因患者亚组而异,这表明表型指导策略不仅可以改进药物治疗,还可以改进手术决策。然而,这些表型仍然是启发式的,具有重叠的特征,有限的验证和不确定的预测价值。未来的研究应完善表型分类,确定可靠的生物标志物,并进行表型分层临床试验,以确认药物和手术干预的匹配。
{"title":"From one-size-fits-all to phenotype-based pharmacotherapy: How far are we in obesity management?","authors":"Theocharis Koufakis ,&nbsp;Luca Busetto","doi":"10.1016/j.coph.2025.102589","DOIUrl":"10.1016/j.coph.2025.102589","url":null,"abstract":"<div><div>Obesity is a global health crisis, projected to affect over one billion adults by 2030. Lifestyle modification strategies—diet, physical activity, and behavioral therapy—have achieved only modest and often unsustainable outcomes. Pharmacotherapy has therefore emerged as a cornerstone of modern obesity care. Glucagon-like peptide-1 (GLP-1) receptor agonists and dual incretin agents such as tirzepatide have demonstrated unprecedented efficacy, with weight reductions approaching surgical outcomes in some populations while improving glycemic and cardiometabolic parameters. These therapeutic advances align with recognition of the pathophysiological heterogeneity of obesity, often conceptualized through four phenotypes: “hungry brain” (impaired satiation), “hungry gut” (impaired satiety), “emotional hunger” (reward-driven eating), and “slow burn” (impaired metabolism). This framework offers a rationale for targeted interventions—GLP-1 receptor agonists for satiety-related phenotypes, naltrexone–bupropion for reward-driven eating, and dual incretin therapies for metabolic inefficiency. Beyond pharmacology, accumulating evidence indicates that surgical outcomes may also differ across patient subgroups, suggesting that phenotype-guided strategies could refine not only medical therapy but also surgical decision-making. However, these phenotypes remain heuristic, with overlapping traits, limited validation, and uncertain predictive value. Future research should refine phenotypic classification, identify reliable biomarkers, and conduct phenotype-stratified clinical trials to confirm matching of pharmacological and surgical interventions.</div></div>","PeriodicalId":50603,"journal":{"name":"Current Opinion in Pharmacology","volume":"86 ","pages":"Article 102589"},"PeriodicalIF":4.2,"publicationDate":"2025-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145727034","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Electro-microbial interplay in the gut–brain axis: An emerging paradigm for gut microbiota modulation via vagus nerve stimulation 电-微生物在肠-脑轴上的相互作用:通过迷走神经刺激调节肠道微生物群的一个新兴范例
IF 4.2 3区 医学 Q1 PHARMACOLOGY & PHARMACY Pub Date : 2025-11-15 DOI: 10.1016/j.coph.2025.102588
Jingwen Liang , Xiunan Li , Chunyang Mao , Zhen Qin , Rui Wang
The treatment of central nervous system disorders remains a clinical challenge, highlighting an urgent need for innovative therapeutic strategies. The gut-brain axis represents a complex bidirectional communication network between the gastrointestinal tract and the brain, with the vagus nerve serving as a critical pathway for signal transmission. Vagus nerve stimulation (VNS), an established therapy for drug-resistant epilepsy and depression, has been shown to modulate the composition and functional output of gut microbiota, which in turn influences disease progression. Concurrently, gut microbiota and their metabolites such as short-chain fatty acids can regulate vagal activity through feedback mechanisms. This bidirectional interaction operates through neural, immune and metabolic pathways. This review provides a systematic review of the mechanisms through which VNS influences gut microbiota, and how microbial products feedback to regulate vagus nerve activity and the integrated pathways underlying this cross-talk, for the sake of providing insights into novel therapeutic approaches targeting the gut-brain interface.
中枢神经系统疾病的治疗仍然是一个临床挑战,迫切需要创新的治疗策略。肠脑轴代表了胃肠道和大脑之间复杂的双向通信网络,迷走神经是信号传递的关键途径。迷走神经刺激(VNS)是一种治疗耐药癫痫和抑郁症的既定疗法,已被证明可以调节肠道微生物群的组成和功能输出,从而影响疾病进展。同时,肠道菌群及其代谢物如短链脂肪酸可以通过反馈机制调节迷走神经活动。这种双向相互作用通过神经、免疫和代谢途径起作用。本综述对VNS影响肠道微生物群的机制、微生物产物如何反馈调节迷走神经活动以及这种串扰背后的综合途径进行了系统综述,以期为针对肠-脑界面的新治疗方法提供见解。
{"title":"Electro-microbial interplay in the gut–brain axis: An emerging paradigm for gut microbiota modulation via vagus nerve stimulation","authors":"Jingwen Liang ,&nbsp;Xiunan Li ,&nbsp;Chunyang Mao ,&nbsp;Zhen Qin ,&nbsp;Rui Wang","doi":"10.1016/j.coph.2025.102588","DOIUrl":"10.1016/j.coph.2025.102588","url":null,"abstract":"<div><div>The treatment of central nervous system disorders remains a clinical challenge, highlighting an urgent need for innovative therapeutic strategies. The gut-brain axis represents a complex bidirectional communication network between the gastrointestinal tract and the brain, with the vagus nerve serving as a critical pathway for signal transmission. Vagus nerve stimulation (VNS), an established therapy for drug-resistant epilepsy and depression, has been shown to modulate the composition and functional output of gut microbiota, which in turn influences disease progression. Concurrently, gut microbiota and their metabolites such as short-chain fatty acids can regulate vagal activity through feedback mechanisms. This bidirectional interaction operates through neural, immune and metabolic pathways. This review provides a systematic review of the mechanisms through which VNS influences gut microbiota, and how microbial products feedback to regulate vagus nerve activity and the integrated pathways underlying this cross-talk, for the sake of providing insights into novel therapeutic approaches targeting the gut-brain interface.</div></div>","PeriodicalId":50603,"journal":{"name":"Current Opinion in Pharmacology","volume":"86 ","pages":"Article 102588"},"PeriodicalIF":4.2,"publicationDate":"2025-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145798269","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Real-world evidence supporting orphan drugs approvals for rare neuromuscular disorders in the European Union and the United States: Review of public assessment reports (2015–2025) 支持欧盟和美国罕见神经肌肉疾病孤儿药批准的真实证据:公共评估报告回顾(2015-2025)
IF 4.2 3区 医学 Q1 PHARMACOLOGY & PHARMACY Pub Date : 2025-11-14 DOI: 10.1016/j.coph.2025.102586
Beliu García-Parra , Josep M. Guiu , Mónica Povedano , Pilar Modamio
Real-world data (RWD) and real-world evidence (RWE) are becoming essential complements to conventional clinical trials for drug assessment, particularly for rare neuromuscular disorders where small patient populations heighten outcome uncertainty. Robust RWE could reduce that uncertainty and inform regulatory decisions on orphan drugs (ODs). To review how the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) have incorporated RWE into OD approvals for neuromuscular diseases from January 2015 to January 2025. We reviewed all publicly available EMA European Public Assessment Reports and FDA review packages for ODs targeting neuromuscular indications. Each document was screened for mention of RWD sources and by the regulatory weight assigned to the resulting RWE. We identified 14 OD approvals by the EMA and 13 by the FDA, with greater use of RWE by the FDA. Indications comprised spinal muscular atrophy (3/3 EMA/FDA), amyotrophic lateral sclerosis (1/3), amyloid neuropathies (2/2), Friedreich ataxia (1/1), Lambert–Eaton syndrome (1/1), myasthenia gravis (2/2), myotonic disorders (1/0), and Duchenne muscular dystrophy (2/1). Among 18 evaluable dossiers, clinical outcome assessments (COA) were reported as follows: patient-reported outcomes - 39.1%, clinician-reported outcomes - 34.7%, observer-reported outcomes - 13.1 %, and performance outcomes - 13.1%. Only tofersen incorporated all COA types. The use of RWE for the evaluation of ODs is increasing for both the FDA and the EMA, more so for the former than for the latter. Harmonized methodological standards and transparent reporting frameworks are urgently needed to generate quality evidence that benefits stakeholders.
真实世界数据(RWD)和真实世界证据(RWE)正在成为药物评估常规临床试验的重要补充,特别是对于罕见的神经肌肉疾病,其中小患者群体增加了结果的不确定性。健全的RWE可以减少这种不确定性,并为孤儿药(ODs)的监管决策提供信息。回顾欧洲药品管理局(EMA)和美国食品和药物管理局(FDA)如何将RWE纳入2015年1月至2025年1月神经肌肉疾病的OD批准。我们审查了针对神经肌肉适应症的ODs的所有公开可用的EMA欧洲公共评估报告和FDA审查包。每份文件都经过筛选,以确定RWD来源,并根据分配给最终RWE的监管权重进行筛选。我们确定了14个由EMA批准的OD和13个由FDA批准的OD, FDA更多地使用了RWE。适应症包括脊髓性肌萎缩症(3/3 EMA/FDA)、肌萎缩性侧索硬化症(1/3)、淀粉样神经病(2/2)、弗里德赖希共济失调症(1/1)、Lambert-Eaton综合征(1/1)、重症肌无力症(2/2)、肌强直性疾病(1/0)和杜氏肌营养不良症(2/1)。在18个可评估的档案中,临床结果评估(COA)的报告如下:患者报告的结果为39.1%,临床报告的结果为34.7%,观察者报告的结果为13.1%,绩效结果为13.1%。只有tofersen合并了所有COA类型。对于FDA和EMA来说,RWE用于ODs评估的使用正在增加,前者比后者更多。迫切需要统一的方法标准和透明的报告框架,以产生有利于利益攸关方的高质量证据。
{"title":"Real-world evidence supporting orphan drugs approvals for rare neuromuscular disorders in the European Union and the United States: Review of public assessment reports (2015–2025)","authors":"Beliu García-Parra ,&nbsp;Josep M. Guiu ,&nbsp;Mónica Povedano ,&nbsp;Pilar Modamio","doi":"10.1016/j.coph.2025.102586","DOIUrl":"10.1016/j.coph.2025.102586","url":null,"abstract":"<div><div>Real-world data (RWD) and real-world evidence (RWE) are becoming essential complements to conventional clinical trials for drug assessment, particularly for rare neuromuscular disorders where small patient populations heighten outcome uncertainty. Robust RWE could reduce that uncertainty and inform regulatory decisions on orphan drugs (ODs). To review how the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) have incorporated RWE into OD approvals for neuromuscular diseases from January 2015 to January 2025. We reviewed all publicly available EMA European Public Assessment Reports and FDA review packages for ODs targeting neuromuscular indications. Each document was screened for mention of RWD sources and by the regulatory weight assigned to the resulting RWE. We identified 14 OD approvals by the EMA and 13 by the FDA, with greater use of RWE by the FDA. Indications comprised spinal muscular atrophy (3/3 EMA/FDA), amyotrophic lateral sclerosis (1/3), amyloid neuropathies (2/2), Friedreich ataxia (1/1), Lambert–Eaton syndrome (1/1), myasthenia gravis (2/2), myotonic disorders (1/0), and Duchenne muscular dystrophy (2/1). Among 18 evaluable dossiers, clinical outcome assessments (COA) were reported as follows: patient-reported outcomes - 39.1%, clinician-reported outcomes - 34.7%, observer-reported outcomes - 13.1 %, and performance outcomes - 13.1%. Only tofersen incorporated all COA types. The use of RWE for the evaluation of ODs is increasing for both the FDA and the EMA, more so for the former than for the latter. Harmonized methodological standards and transparent reporting frameworks are urgently needed to generate quality evidence that benefits stakeholders.</div></div>","PeriodicalId":50603,"journal":{"name":"Current Opinion in Pharmacology","volume":"86 ","pages":"Article 102586"},"PeriodicalIF":4.2,"publicationDate":"2025-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145658448","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Acupuncture for depression: Decoding neuroimmune crosstalk and targeting anti-inflammatory mechanisms 针灸治疗抑郁症:解码神经免疫串扰和靶向抗炎机制
IF 4.2 3区 医学 Q1 PHARMACOLOGY & PHARMACY Pub Date : 2025-11-14 DOI: 10.1016/j.coph.2025.102585
Anni Shi , Wenjing Li , Xiaoling Liu , Jun Lu , Jianyou Guo
Depression, a leading global health burden, involves neuroimmune dysregulation and neuroinflammation. As a promising non-pharmacological approach, acupuncture has been supported by numerous studies as an effective intervention for alleviating depression. The antidepressant mechanisms of acupuncture involve a multitarget modulation of neuroimmune crosstalk, such as restoring hypothalamic-pituitary-adrenal (HPA) axis homeostasis, inhibiting microglial and astrocytic activation, regulating autophagy, inhibiting key inflammatory signaling pathways, activating anti-inflammatory pathways via the vagus nerve, and rebalancing gut–brain axis communication by modifying microbiota. Integrating acupuncture with advanced neuromodulation techniques may enhance its effectiveness in treating depression. It needs further study to validate acupuncture as an effective therapeutic strategy in the field of neuroimmunology for depression. This review summarizes evidence elucidating how acupuncture regulates neuroimmune crosstalk in depression. It not only provides a scientific basis for its application but also advances the understanding of the pathophysiology of depression by highlighting the interplay between neuroimmune interaction and inflammatory pathways.
抑郁症是全球主要的健康负担,涉及神经免疫失调和神经炎症。作为一种很有前途的非药物治疗方法,针灸作为一种缓解抑郁症的有效干预手段得到了大量研究的支持。针灸的抗抑郁机制涉及神经免疫串扰的多靶点调节,如恢复下丘脑-垂体-肾上腺(HPA)轴稳态、抑制小胶质细胞和星形胶质细胞的激活、调节自噬、抑制关键的炎症信号通路、激活迷走神经的抗炎通路,以及通过改变微生物群来重新平衡肠-脑轴通讯。将针刺与先进的神经调节技术相结合,可以提高其治疗抑郁症的有效性。针刺作为神经免疫学治疗抑郁症的有效方法尚需进一步研究。本文综述了针灸如何调节抑郁症患者的神经免疫串扰的证据。它不仅为其应用提供了科学依据,而且通过强调神经免疫相互作用和炎症途径之间的相互作用,促进了对抑郁症病理生理学的理解。
{"title":"Acupuncture for depression: Decoding neuroimmune crosstalk and targeting anti-inflammatory mechanisms","authors":"Anni Shi ,&nbsp;Wenjing Li ,&nbsp;Xiaoling Liu ,&nbsp;Jun Lu ,&nbsp;Jianyou Guo","doi":"10.1016/j.coph.2025.102585","DOIUrl":"10.1016/j.coph.2025.102585","url":null,"abstract":"<div><div>Depression, a leading global health burden, involves neuroimmune dysregulation and neuroinflammation. As a promising non-pharmacological approach, acupuncture has been supported by numerous studies as an effective intervention for alleviating depression. The antidepressant mechanisms of acupuncture involve a multitarget modulation of neuroimmune crosstalk, such as restoring hypothalamic-pituitary-adrenal (HPA) axis homeostasis, inhibiting microglial and astrocytic activation, regulating autophagy, inhibiting key inflammatory signaling pathways, activating anti-inflammatory pathways via the vagus nerve, and rebalancing gut–brain axis communication by modifying microbiota. Integrating acupuncture with advanced neuromodulation techniques may enhance its effectiveness in treating depression. It needs further study to validate acupuncture as an effective therapeutic strategy in the field of neuroimmunology for depression. This review summarizes evidence elucidating how acupuncture regulates neuroimmune crosstalk in depression. It not only provides a scientific basis for its application but also advances the understanding of the pathophysiology of depression by highlighting the interplay between neuroimmune interaction and inflammatory pathways.</div></div>","PeriodicalId":50603,"journal":{"name":"Current Opinion in Pharmacology","volume":"86 ","pages":"Article 102585"},"PeriodicalIF":4.2,"publicationDate":"2025-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145658447","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Current Opinion in Pharmacology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1